The company's new president and possible CEO is expected to have significant latitude to change things.
The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.
AstraZeneca has been awarded $76 million in damages in a ruling over Apotex's sales of a generic version of Prilosec.
Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle patent litigation surrounding Impax's generic version of OxyContin.
Following a Warning Letter from the FDA, 23andMe has stopped marketing its DNA test.
Chronic disease patients seek online support and information, and show little love for branded websites.
The agency extended the review time for Biogen's Alprolix by three months.